nach oben

The Patient - Patient-Centered Outcomes Research

Erschienen in:

01.02.2016 | Original Research Article

Preferences and Stated Adherence for Antibiotic Treatment of Cystic Fibrosis Pseudomonas Infections

verfasst von: Ateesha Farah Mohamed, F. Reed Johnson, Maria-Magdalena Balp, Frederico Calado

Erschienen in: The Patient - Patient-Centered Outcomes Research | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Objective

Our objective was to quantify preferences and stated adherence for inhaled antibiotic treatments in cystic fibrosis (CF).

Methods

Adult CF patients and parents of pediatric patients in the US who were members of the Cystic Fibrosis Foundation and who had Pseudomonas aeruginosa at least twice a year completed an online, discrete-choice experiment survey (response rate 4.4 %). Respondents answered five treatment-choice questions evaluating pairs of hypothetical CF treatment profiles. Stated-adherence questions followed two randomly selected treatment-choice questions. Data were analyzed using random-parameters logit (RPL). For a combination of attribute levels, the utility is estimated by summing the relevant attribute-level parameter estimates. For the stated-adherence questions, we tabulated the changes in the percentages of respondents who would be 95 % adherent for various changes in inhaled antibiotic-medication administration features.

Results

The final sample was 271 adult patients and 209 parents. Switching from a 30-min nebulizer twice daily to a 10-min dry powder inhaler (DPI) twice daily was 6.3 times more important for patients and 2.0 times more important for parents than an improvement in dry cough side effect from moderate to mild. Stated adherence for respondents was 20–30 % greater for DPIs versus nebulizers.

Conclusions

Lower frequency of administration, shorter administration times for a given device, and milder dry cough appear to improve stated adherence to antibiotic treatment of CF lung infections.

Nur mit Berechtigung zugänglich

Taste heterogeneity is differences in tastes across individuals. Controlling for taste heterogeneity overcomes the independence from irrelevant alternatives (IIA) property in choice models by creating correlations in the random component of utility that ‘break’the undesirable IIA property and allow any substitution pattern to be found.

Kerem E, Corey M, Gold R, Levison H. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr. 1990;116(5):714–9.PubMedCrossRef

Pritt B, O’Brien L, Winn W. Mucoid Pseudomonas in cystic fibrosis. Am J Clin Pathol. 2007;128(1):32–4.PubMedCrossRef

Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34(2):91–100.PubMedCrossRef

Flume PA, O’Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey-Courand DB, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176(10):957–69.PubMedCrossRef

Eakin MN, Bilderback A, Boyle MP, Mogayzel PJ, Riekert KA. Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros. 2011;10(4):258–64.PubMedPubMedCentralCrossRef

Latchford G, Duff A, Quinn J, Conway S, Conner M. Adherence to nebulised antibiotics in cystic fibrosis. Patient Educ Couns. 2009;75(1):141–4.PubMedCrossRef

Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros. 2009;8(2):91–6.PubMedPubMedCentralCrossRef

Blau H, Mussaffi H, Mei Zahav M, Prais D, Livne M, Czitron BM, et al. Microbial contamination of nebulizers in the home treatment of cystic fibrosis. Child Care Health Dev. 2007;33(4):491–5.PubMedCrossRef

Lester MK, Flume PA, Gray SL, Anderson D, Bowman CM. Nebulizer use and maintenance by cystic fibrosis patients: a survey study. Respir Care. 2004;49(12):1504–8.PubMed

10.

Fitzgerald D. Non-compliance in adolescents with chronic lung disease: causative factors and practical approach. Paediatr Respir Rev. 2001;2(3):260–7.PubMed

11.

Abbott J, Gee L. Contemporary psychosocial issues in cystic fibrosis: treatment adherence and quality of life. Disabil Rehabil. 1998;20(6–7):262–71.PubMedCrossRef

12.

Weiner JR, Toy EL, Sacco P, Duh MS. Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature. Expert Opin Pharmacother. 2008;9(5):751–66.PubMedCrossRef

13.

Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health-a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14(4):403–13.PubMedCrossRef

14.

Thurstone L. A law of comparative judgement. Psychol Rev. 1927;34:237–86.CrossRef

15.

McFadden D. Conditional logit analysis of qualitative choice behavior. In: Zarembka P, editor. Frontiers in econometrics. New York: Academic Press; 1974. p. 105–42.

16.

Hauber AB, Mohamed AF, Johnson FR, Falvey H. Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents. Diabet Med. 2009;26(4):416–24.PubMedCrossRef

17.

Marshall D, Bridges JF, Hauber B, Cameron R, Donnalley L, Fyie K, et al. Conjoint analysis applications in health: how are studies being designed and reported? An update on current practice in the published literature between 2005 and 2008. Patient. 2010;3(4):249–56.PubMedCrossRef

18.

Train K. Discrete choice methods with simulation. 1st ed. Cambridge: Cambridge University Press; 2003.CrossRef

19.

Hensher DA, Rose JM, Greene WH. Applied choice analysis: a primer. Cambridge: Cambridge University Press; 2005.CrossRef

20.

Fisher RJ. Social desirability bias and the validity of indirect questioning. J Consum Res. 1993;l20(2):303–15.CrossRef

21.

Johnson F, Lancsar E, Marshall D, Kilambi V, Muhlbacher A, Regier DA, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013;16(1):3–13.CrossRef

22.

Train K, Sonnier G. Mixed logit with bounded distributions of correlated partworths. In: Scarpa R, Alberini A, editors. Applications of simulation methods in environmental and resource economics. Dordrecht: Springer; 2005. p. 117–34.CrossRef

23.

Bech M, Gyrd-Hansen D. Effects coding in discrete choice experiments. Health Econ. 2005;14(10):1079–83.PubMedCrossRef

24.

Mohamed AF, Hauber AB, Neary MP. Patient benefit-risk preferences for targeted agents in the treatment of renal cell carcinoma. Pharmacoeconomics. 2011;29(11):977–88.PubMedCrossRef

25.

Hechmati G, Hauber AB, Arellano J, Mohamed AF, Qian Y, Gatta F, et al. Patients‘ preferences for bone metastases treatments in France, Germany and the United Kingdom. Support Care Cancer. 2015;23(1):21–8.PubMedPubMedCentralCrossRef

26.

Cystic Fibrosis Foundation. Patient registry annual data report 2012. 2012.

27.

Konstan MW, Geller DE, Minic P, Brockhaus F, Zhang J, Angyalosi G. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol. 2011;46:230–8.PubMedPubMedCentralCrossRef

28.

Barbosa CD, Balp M-M, Kulich K, Germain N, Rofail D. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence. 2012;6:39–48.PubMedPubMedCentralCrossRef

29.

Braccini G, Festini F, Boni V, Neri AS, Galici V, Campana S, et al. The costs of treatment of early and chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Chemother. 2009;21(2):188–92.PubMedCrossRef

30.

Ouyang L, Grosse SD, Amendah DD, Schechter MS. Healthcare expenditures for privately insured people with cystic fibrosis. Pediatr Pulmonol. 2009;44(10):989–96.PubMedCrossRef

Titel: Preferences and Stated Adherence for Antibiotic Treatment of Cystic Fibrosis Pseudomonas Infections
verfasst von: Ateesha Farah Mohamed
F. Reed Johnson
Maria-Magdalena Balp
Frederico Calado
Publikationsdatum: 01.02.2016
Verlag: Springer International Publishing
Erschienen in: The Patient - Patient-Centered Outcomes Research / Ausgabe 1/2016
Print ISSN: 1178-1653
Elektronische ISSN: 1178-1661
DOI: https://doi.org/10.1007/s40271-015-0124-1

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Preferences and Stated Adherence for Antibiotic Treatment of Cystic Fibrosis Pseudomonas Infections

Abstract

Objective

Methods

Results

Conclusions

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

Depressive Symptoms, Cardiac Anxiety, and Fear of Body Sensations in Patients with Non-Cardiac Chest Pain, and Their Relation to Healthcare-Seeking Behavior: A Cross-Sectional Study

How Well Do the Generic Multi-attribute Utility Instruments Incorporate Patient and Public Views Into Their Descriptive Systems?

Focus Groups in Elderly Ophthalmologic Patients: Setting the Stage for Quantitative Preference Elicitation

Assessment of Transdermal Buprenorphine Patches for the Treatment of Chronic Pain in a UK Observational Study

Validation of a Patient Satisfaction Scale in Patients Undergoing Bowel Preparation Prior to Colonoscopy

Novel Statistical Approach to Determine Inflammatory Bowel Disease: Patients’ Perspectives on Shared Decision Making